We randomly assigned @ patients , of whom @ ( @ rhEPO and @ placebo ) withdrew consent and @ ( placebo ) became ineligible ( retinal thrombosis , respiratory insufficiency , SOD@ mutation ) before receiving treatment ; @ receiving rhEPO and @ placebo were eligible for analysis .